Question: Are Nordstrom and Vertex Pharmaceuticals headquartered in the same state?

Context articles: Emcure Pharmaceuticals
Vertex Pharmaceuticals
Nordstrom
The Billion-Dollar Molecule
Telaprevir
Vicki Sato
Lumacaftor
David Altshuler
Derek Lowe (chemist)
Biricodar

Emcure Pharmaceuticals headquartered at Pune in West India is an Indian pharmaceutical company.
 The company's products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.
Vertex Pharmaceuticals is an American Pharmaceutical company based in Boston, Massachusetts.
Nordstrom, Inc. ( ) is an American chain of luxury department stores headquartered in Seattle, Washington.
 Founded in 1901 by John W. Nordstrom and Carl F. Wallin, the company began as a shoe retailer and expanded its inventory to include clothing, accessories, handbags, jewelry, cosmetics, and fragrances. Select Nordstrom stores also include wedding and home furnishings departments.
The Billion-Dollar Molecule is a book by journalist Barry Werth about the founding and early research efforts of the American biotechnology company Vertex Pharmaceuticals, which was founded in 1989 by Joshua Boger and was among the first biotechnology companies to adopt an explicit strategy of rational drug design as opposed to techniques based on combinatorial chemistry.
Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C codeveloped by Vertex Pharmaceuticals and Johnson & Johnson.
 It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3.4A serine protease.
 Telaprevir is only indicated for use against hepatitis C genotype 1 viral infections and has not been proven to have an effect on or being safe when used for other genotypes of the virus.
 The standard therapy of pegylated interferon and ribavirin is less effective on genotype 1.
Vicki L. Sato is a professor of management practice at Harvard Business School and a professor of the practice in the department of molecular and cell biology at Harvard University.
 She earned her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University focusing on the genetics of photosynthesis under the guidance of Paul Levine.
 She then did her postdoctoral work at University of California, Berkeley with Kenneth Sauer and Stanford Medical Center with Leonard Herzenberg where she shifted fields from biophysics into immunology.
 Initially, she returned to Harvard as a Professor in the Department of Cell and Developmental Biology.
 During that time, she co-taught immunology with Walter Gilbert who was beginning to found Biogen Inc. along with Phil Sharp, Charles Weissmann, and Kenneth Murray.
 During her sabbatical after eight years at Harvard, she became involved with a startup and eventually joined Biogen Inc. from 1984 to 1992 and left as the VP of Research and a member of the Scientific Board.
 She then joined Vertex Pharmaceuticals as the Chief Scientific Officer before becoming the Senior VP of Research and Development and ultimately serving as the President of Vertex Pharmaceuticals from 2000 to 2005.
 During her tenure, the drugs Avonex, Tysabri, and Telaprevir were developed.
Lumacaftor (VX-809) is a pharmaceutical drug that acts as a chaperone during protein folding and increases the number of CFTR proteins that are trafficked to the cell surface.
 It is available in a single pill with ivacaftor; the combination, lumacaftor/ivacaftor (brand name Orkambi), is used to treat people with cystic fibrosis who have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease.
 It was developed by Vertex Pharmaceuticals and the combination was approved by the FDA in 2015.
 As of 2015 lumacaftor had no medical use on its own.
David Matthew Altshuler is a clinical endocrinologist and human geneticist.
 He is Executive Vice President, Global Research and Chief Scientific Officer at Vertex Pharmaceuticals.
 Prior to joining Vertex in 2014, he was at the Broad Institute of Harvard and MIT.
, and was a Professor of Genetics and Medicine at Harvard Medical School, and in the Department of Biology at Massachusetts Institute of Technology.
 He was also a faculty member in the Department of Molecular Biology, Center for Human Genetic Research, and the Diabetes Unit, all at Massachusetts General Hospital.
 He was one of four Founding Core Members of the Broad Institute, and served as the Institute's Deputy Director, Chief Academic Officer, and Director of the Program in Medical and Population Genetics.
Dr. Derek Lowe is a chemistry blogger and medicinal chemist working on preclinical drug discovery, previously as a Research Fellow at Vertex Pharmaceuticals.
 Lowe (born in Harrisburg, Arkansas) got his BA from Hendrix College and his PhD in organic chemistry from Duke University, doing his doctoral research studying the organic synthesis of natural products, before spending time in Germany on a Humboldt Fellowship on his post-doc.
Biricodar (INN, codename VX-710, marketed as the dicitrate salt under the trade name Incel) is a pharmaceutical drug released by Vertex Pharmaceuticals in 1999 to help treat ovarian cancer patients.